Global Axial Spondyloarthritis (axSpA) Market Projected to Surpass $9.05 Billion by 2029 with 8% Annual Growth

What combination of drivers is leading to accelerated growth in the axial spondyloarthritis (axspa) market?
The axial spondyloarthritis (axSpa) market is predicted to be driven by the growing incidence of spondyloarthritis. This chronic disease primarily affects the axial skeleton, which includes the spine and sacroiliac joints. The increased occurrence of axial spondyloarthritis (axSpA) can be linked to the rising numbers of the elderly population and spine injuries resulting from even minor mishaps. Various treatments focusing on pain relief, inflammation reduction, and improving the lifestyle of axSpA patients are available. For example, the Musculoskeletal Health Report 2023 by Versus Arthritis, a UK-based charity for arthritis patients, stated that in 2023, about 60,000 individuals suffered from axial spondyloarthritis. It also noted that approximately 2,200 adults annually are given a new diagnosis of this condition as of 2022. This growing incidence of axial spondyloarthritis (axSpa) is thus stimulating the expansion of the axial spondyloarthritis (axSpa) market.

Get Your Axial Spondyloarthritis (axSpA) Market Report Here:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What is the projected compound annual growth rate (CAGR) of the axial spondyloarthritis (axspa) market from 2025 to 2034, and what factors influence it?
The market for axial spondyloarthritis (axspa) has shown significant expansion in the past few years. It's projected to surge from a valuation of $6.08 billion in 2024 to an impressive $6.58 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. This growth during the historical period is credited to factors such as enhancements in diagnostic procedures, advancements in biological therapies, an increased understanding of the disease, progress in genetic research, and strides made in clinical trials.

Strong expansion is projected for the Axial Spondyloarthritis (axspa) market in the next several years. By 2029, it's estimated to reach a value of $9.05 billion with a compound annual growth rate (CAGR) of 8.3%. This predicted growth in the forecast period can be credited to advancements in the identification of biomarkers, personalized therapies, the integration of digital health, wider treatment options, and support from healthcare policies. Expect to see trends such as early intervention strategies, patient-oriented care, telemedicine and remote consultations, studies on disease mechanisms, and shared decision-making during this forecast period.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

How are the latest trends influencing the growth of the axial spondyloarthritis (axspa) market?
The main trend making waves in the axial spondyloarthritis (axSpA) market is product innovation. Leading companies in the axSpA market are formulating new medications to maintain their competitive edge. For example, in June 2023, the Belgium-based pharmaceutical entity, UCB SA, gained approval from the New European Commission for the marketing of BIMZELX (bimekizumab). This drug is designed to treat adults suffering from active axSpA, non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) displaying signs of inflammation as shown by elevated C-reactive protein. The approval by the European Union (EU) marks the first worldwide marketing licenses for axSpA for this medication.

What are the major segments of the axial spondyloarthritis (axspa) market and their role in driving growth?
The axial spondyloarthritis (axSpA) market covered in this report is segmented -

1) By Types: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA, Asymptomatic nr-axSpA

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590

Which regions are key players in the growth of the axial spondyloarthritis (axspa) market?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the key firms paving the way for growth in the axial spondyloarthritis (axspa) market?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Is Covered In The Axial Spondyloarthritis (axSpA) Global Market Report?

• Market Size Forecast: Examine the axial spondyloarthritis (axspa) market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the axial spondyloarthritis (axspa) market for a structured understanding.
• Key Players Overview: Analyze major players in the axial spondyloarthritis (axspa) market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the axial spondyloarthritis (axspa) market.
• Segment Contributions: Evaluate how different segments drive overall growth in the axial spondyloarthritis (axspa) market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the axial spondyloarthritis (axspa) market.
• Industry Challenges: Identify potential risks and obstacles affecting the axial spondyloarthritis (axspa) market.
• Competitive Landscape: Review strategic developments in the axial spondyloarthritis (axspa) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.